French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
Category: #health  By Pankaj Singh  Date: 2020-01-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding

A clinical stage biotechnology company, PDC*line Pharma, focused upon developing a new class of effective and scalable active immunotherapies for treating cancers, recently announced completion of a Series B round of funding. The company has raised a total of USD 22.2 million.

The new funding round, which is the first after the last fundraising round in 2017, has been able to capture the attention of new investors, acquiring a further capital increase of USD 15.5 million. Moreover, the biotech company will receive an amount of USD 6.8 million in loans and subsidies from the region of Wallonia located in Belgium. Apparently, the region has backed the company since it started its operations there, in 2016.

As per sources close to the matter, PDC*line Pharma has attracted 5 new investors-  two Belgian funds, Sambrinvest (the investment fund of Charleroi) and SRIW (The Regional Investment Company of Wallonia), Korean Investment Partners( the leading multi-billion dollar South-Korean fund) and  two further South-Korean funds, UTC 2019 BIOVENTUREFUND and Shinhan-Cognitive Start-up Fund.

These new investors will be joining the company’s historical investors, which include SFPI-FPIM, Investment Company, the Belgian Federal Holding, Noshaq Group (ex-Meusinvest), a group of international business angels, the INVESTSUD Group/ Financière Spin-off Luxembourgeoise, and renowned entrepreneurs.

Eric Halioua, President & Chief Executive Officer of PDC*line Pharma was reportedly quoted saying that the company is humbled by the trust its investors have placed in them and the opportunity to successfully complete this fund raising.

Halioua further remarked that the competitive edge of the company’s vaccinal platform in cancer immunotherapy and the noteworthy achievements they have made over the last 3 years, including the start of phase I/II trials in Belgium and France in NSCLC  (non-small-cell lung cancer) and signing of a significant licensing deal with the Asian LG-Chem, have proved to be key factors, which have positively influenced investors’ decisions.

Source Credit: https://www.pdc-line-pharma.com/news/pdcline-pharma-raises-eu20-million-222m-series-b-financing-round

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Construction sector accountable for 37% of carbon emissions, UN report
Construction sector accountable for 37% of carbon emissions, UN report
By Pankaj Singh

A new research by the United Nations shows a grim picture of the climate situation. The report states that 37% of energy-related carbon dioxide emissions are coming from the construction sector. According to the UN, lockdowns imposed worldwide durin...

Alaska Airlines launches new investment arm to develop mobility tech
Alaska Airlines launches new investment arm to develop mobility tech
By Pankaj Singh

Alaska Airlines, a major American airline, has introduced a new venture capital subdivision called Alaska Star Ventures. The launch comes at a time when the aviation sector is looking to develop technologies that help decarbonize air travel. Alaska ...

Bettervest invests in Oakridge Rooftops to support solar projects
Bettervest invests in Oakridge Rooftops to support solar projects
By Pankaj Singh

Oakridge Rooftops Pvt. Ltd., a solar energy company based in India, has reportedly secured funding from Germany-based crowdfunding platform, Bettervest Gmbh. The solar firm has raised the funding for urban solar projects in New Delhi. Oakridge CEO, ...